Calgary, Alberta--(Newsfile Corp. - December 11, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that in accordance with its stock option plan, it has granted on December 11, 2025, subject to regulatory approval, a total of 963,000 stock options to purchase common shares of Hemostemix (the "Options") to directors, officers, employees and consultants of Hemostemix.Of the Options granted, 663,000 vest immediately and 330,000 vest as to 50% ...

Hemostemix Inc. Announces FDA Pre-IND Meeting and NBPP of $960,000December 10, 2025 11:17 AM EST | Source: Hemostemix Inc.Calgary, Alberta--(Newsfile Corp. - December 10, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from vascular dementia, angina, ischemic cardiomyopathy, congestive heart failure, non-ischemic dilated cardiomyop ...

Hemostemix Welcomes Shaune Harding, OStJ, RN as Director of Patient Care & Clinical OperationsDecember 04, 2025 9:10 AM EST | Source: Hemostemix Inc.Calgary, Alberta--(Newsfile Corp. - December 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), a leader in autologous stem cell therapeutics for ischemic diseases, is pleased to announce the appointment of Shaune Harding, OStJ, RN non-practicing, as Director of Patient Care & Clinical Operations. In ...

Hemostemix Featured at Innovations in Wound Healing 2025, Key West, December 11-14December 03, 2025 2:05 PM EST | Source: Hemostemix Inc.Calgary, Alberta--(Newsfile Corp. - December 3, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce its participation as a premier regenerative medicine company at Innovations in Wound Healing 2025 in Key West, Florida, December 11-14, where global leaders in vascular surgery, wound care, diabe ...

Core Insights - Hemostemix Inc. has initiated its strategy to acquire cardiology practices, starting with two prominent cardiologists in the Dominican Republic, Dr. Roberto Manuel Fernandez-de-Castro and Dr. Hector Rosario Figueroa, for 2,000,000 shares each [1][11] - The long-term strategy aims to integrate profitable medical practices to enhance the commercialization of ACP-01 treatments, creating a sustainable patient flow for the company [2][6] - The two cardiologists have extensive experience, having treated over 200 patients with ACP-01, positioning them as key figures in the company's expansion efforts [3][7] Company Strategy - The acquisition of these practices is part of a broader plan to establish a clinical and commercial presence internationally, with a focus on patient treatment flow and increasing practitioner engagement [2][6] - Hemostemix aims to replicate its business model across various markets, including Florida, Puerto Rico, and Canada, leveraging the expertise of the acquired cardiologists [6][7] Clinical Expertise - Dr. Fernandez-de-Castro and Dr. Figueroa will contribute their expertise in treating various cardiovascular conditions, including Angina, Ischemic and Dilated Cardiomyopathy, Congestive Heart Failure, Peripheral Arterial Disease, Chronic Limb-Threatening Ischemia, and Vascular Dementia [5][4] - Their established reputations and patient bases in the Dominican Republic are expected to facilitate the implementation of ACP-01 therapy [4][5] Financial Aspects - The TSXV has approved an extension for a non-brokered private placement, allowing Hemostemix to raise funds at $0.11 per unit, with total gross proceeds of $461,230 raised to date [8] - Each unit consists of one common share and one warrant, with the potential for additional shares to be acquired at $0.15 per share [8] Company Background - Hemostemix is an autologous stem cell therapy platform company, recognized for its development of VesCell™ (ACP-01), which has shown promising results in clinical studies for various cardiovascular diseases [9] - The company has completed seven clinical studies involving 318 subjects, demonstrating the safety and efficacy of ACP-01 [9]

Core Insights - Hemostemix Inc. is advancing ACP-01, an autologous stem cell therapy, for the treatment of vascular dementia, with Dr. William R. Shankle leading the Phase I clinical trial [1][8][10] Company Overview - Hemostemix Inc. specializes in autologous stem cell therapies, particularly VesCell™ (ACP-01), targeting various conditions including vascular dementia, chronic limb threatening ischemia, and congestive heart failure [1][12] - The company has completed seven clinical studies involving 318 subjects and has published results in eleven peer-reviewed publications [12] Clinical Trial Details - The Phase I clinical trial protocol for ACP-01 has been submitted to an Institutional Review Board (IRB) for ethical review, with revisions made based on initial comments [9][10] - Dr. Shankle is reviewing a patient database of approximately 500 individuals diagnosed with cognitive impairment to identify up to 30 patients for the trial [10] Dr. William R. Shankle's Background - Dr. Shankle has over 35 years of medical practice, focusing on cognitive disorders and has been involved in numerous clinical programs and public education initiatives [2][3] - He is the founder of The Shankle Clinic and has held leadership roles at the University of California, Irvine, contributing to advancements in the understanding of vascular dementia [3][4] ACP-01 and Vascular Dementia - ACP-01 is designed to promote angiogenesis and microvascular repair, addressing the vascular underpinnings of vascular dementia [5][8] - The therapy has shown safety and clinical relevance in treating other conditions, with significant outcomes reported in previous studies [12]

Core Insights - Hemostemix Inc. has received conditional approval from the TSX Venture Exchange for a non-brokered private placement amounting to CDN $280,594, involving the issuance of 2,244,752 Common Shares at a price of CDN $0.125 per share [1][2] Company Overview - Hemostemix is a leading autologous stem cell therapy company, founded in 2003, specializing in VesCell™ (ACP-01) for various cardiovascular conditions [4] - The company has completed seven clinical studies involving 318 subjects, with results published in 11 peer-reviewed publications [4] - ACP-01 has shown significant clinical relevance and safety as a treatment for conditions such as peripheral arterial disease and chronic limb threatening ischemia, with a reported 0% mortality rate in a specific patient population over 4.5 years [4] Use of Proceeds - The proceeds from the private placement will be allocated to general working capital purposes, supporting ongoing operational expenses and business development activities [2] Regulatory Compliance - All securities issued in connection with the offering are subject to a four-month hold period under Canadian securities laws [3]

Core Insights - Hemostemix Inc. is set to showcase its innovative angiogenic cell therapy, ACP-01, at the Innovations in Wound Care Conference, emphasizing its potential to improve circulation and heal wounds for patients with advanced conditions like Peripheral Arterial Disease and Critical Limb-Threatening Ischemia [1][3] Company Overview - Hemostemix operates in the regenerative medicine sector, focusing on autologous stem cell therapies, particularly the VesCell™ (ACP-01) treatment, which has shown significant clinical success in healing chronic wounds [7] - The company has completed multiple clinical studies, demonstrating the efficacy of ACP-01 in saving limbs from amputation and improving patient outcomes [2][5] Market Potential - The wound care market in Florida is estimated to be worth $500-$600 million, with a projected growth rate of 5-6% CAGR, expected to reach $700-$800 million in the next five years [3] - The global wound care market is anticipated to exceed $20 billion by 2030, driven by increasing rates of diabetes, vascular disease, and chronic wounds [4][6] Clinical Evidence - Clinical trials have shown that ACP-01 significantly reduces ulcer size, with treated patients experiencing a decrease from a mean of 146 mm² to 0.48 mm² within three months [5] - The treatment group in clinical studies reported a 0% mortality rate and a 4.8% amputation rate, compared to a 25% amputation rate in the placebo group [5] Strategic Positioning - Hemostemix is positioned as a first-mover in the regenerative medicine space for limb salvage, with ACP-01 already available under Florida SB-1768, addressing a significant unmet medical need [6]

Core Viewpoint - Hemostemix Inc. has successfully closed the first tranche of a non-brokered private placement, raising $461,230 through the issuance of 4,193,000 units at a price of $0.11 per unit, aimed at supporting its autologous stem cell therapy, VesCell™ [1][5] Group 1: Offering Details - The offering consists of units that include one common share and one common share purchase warrant, with each warrant allowing the purchase of an additional common share at $0.15 for two years [2] - The company paid approximately $23,698.40 in cash finder's fees and issued 215,440 finder's options, each allowing the purchase of one common share at $0.15 for 24 months [4] - The offering is subject to regulatory approvals and all securities issued will have a four-month hold period under Canadian securities laws [7] Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for general working capital and to support ongoing operations, particularly the marketing and sales of VesCell™ [5] Group 3: Company Background - Hemostemix is a leader in autologous stem cell therapy, having developed and patented VesCell™ (ACP-01), and has completed seven clinical studies with 318 subjects [8] - The company has reported significant clinical outcomes, including a 0% mortality rate in a specific patient population compared to a 50% five-year mortality rate, and an 83% wound healing rate in patients followed for up to 4.5 years [8]

Core Insights - Hemostemix Inc. is hosting a webinar focused on its autologous stem cell therapy, ACP-01, aimed at vascular surgeons in Florida, particularly for patients suffering from chronic limb-threatening ischemia (CLTI) who have no revascularization options [1][3][4] Company Overview - Hemostemix is a leader in autologous stem cell therapy, offering VesCell™ (ACP-01) for various conditions including angina, peripheral arterial disease, and chronic limb-threatening ischemia [1][8] - The company has completed seven clinical studies involving 318 subjects, with results published in eleven peer-reviewed journals [8] - ACP-01 has shown promising clinical outcomes, including a 0% mortality rate and an 83% wound healing rate in patients followed for up to 4.5 years [8] Webinar Details - The webinar is scheduled for October 29, 2025, and will provide Florida-based practitioners with clinical knowledge and operational tools to implement ACP-01 therapy [3][5] - Attendees will receive resources such as patient screening tools and compliance checklists specific to Florida regulations [5][7] Clinical Context - Amputation rates among no-option CLTI patients are high, with 12,059 cases reported in 2023, highlighting the need for effective alternatives like ACP-01 [2] - ACP-01 is designed to stimulate angiogenesis and promote natural tissue healing using the patient's own blood-derived cells, offering a minimally invasive treatment option [2][7]